Desentum
  • Home
  • Technology
  • Company
  • News
  • Contact
  • Suomi
Select Page
Desentum raised 8 M€ to advance clinical development of lead allergy vaccine candidate

Desentum raised 8 M€ to advance clinical development of lead allergy vaccine candidate

by aisla@raikee.fi | Jan 21, 2022 | News

Desentum Oy completed a First-in-Human clinical study last year with an immunotherapeutic hypoallergen targeted for treating birch pollen allergy. In January 2022, the company raised 8 million euros in a funding round arranged by Springvest Oyj. Desentum intends to...
Desentum reports positive findings for the First-in-Human clinical study of lead product candidate in birch pollen allergic adults

Desentum reports positive findings for the First-in-Human clinical study of lead product candidate in birch pollen allergic adults

by aisla@raikee.fi | Oct 25, 2021 | News

Today, Desentum announced positive First-in-Human clinical data of DM-101, its lead candidate for treatment of birch pollen allergy. DM-101 was found to be safe and well tolerated in a dose regimen of 5 ascending doses, and immunological marker results indicated a...
Desentum reports positive findings for the First-in-Human clinical study of lead product candidate in birch pollen allergic adults

Dosing completed for Desentum’s First-in-Human clinical study of DM-101

by aisla@raikee.fi | May 11, 2021 | News

Dosing has been completed for all study subjects in Desentum’s First-in-Human clinical study of DM-101, a novel allergy vaccine intended for treating birch pollen allergy. Last follow-up visits will be completed during Q2/2021 and study results are expected in...
Desentum reports positive findings for the First-in-Human clinical study of lead product candidate in birch pollen allergic adults

Clinical study with birch pollen hypoallergen DM-101 continues

by aisla@raikee.fi | Nov 30, 2020 | News

First-in-Human clinical study with birch pollen hypoallergen DM-101 has been restarted after a temporary halt. In early 2020, Desentum initiated a clinical study to evaluate the safety and tolerability of DM-101, a hypoallergen designed for treating birch pollen...
Desentum reports positive findings for the First-in-Human clinical study of lead product candidate in birch pollen allergic adults

First-in-Human clinical study with DM-101 paused due to corona virus pandemic

by aisla@raikee.fi | Mar 26, 2020 | News

Clinical study initiated in January 2020 with birch pollen hypoallergen DM-101 was suspended in March. The main reason for suspension is that the corona virus epidemic has brought about restrictions in the operations at the study site. In January, Desentum initiated a...
« Older Entries

Viimeisimmät artikkelit

  • Desentum to present clinical results of investigational birch pollen allergy vaccine DM-101PX and scientific discoveries about peanut allergy at the world’s largest allergy congress
  • Desentum reports strong safety and immunological data from Phase 1 clinical study with investigational birch pollen allergy vaccine DM-101PX
  • Ilmoitus osakkeiden siirtymisestä Desentum Oy:n osakkeenomistajille
  • Pekka Mattila conferred as Honorary Doctor at the University of Eastern Finland
  • Desentum raised 12 million euros for advancing allergy vaccine development

Viimeisimmät kommentit

No comments to show.

DESENTUM OY

Tekniikantie 14, 02150 Espoo, Finland
info@desentum.fi

  • Follow
  • Follow

© Desentum Oy

Privacy policy
​​Cookie settings
Website: Räikee Oy

© Desentum Oy

Tietosuojaseloste
​​Evästeasetukset
Nettisivut: Räikee Oy